Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
sharewise4d
Novavax Stock: Narrowing Losses Drive Market Confidence
Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...
Novavax, Inc.: Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...
Hosted on MSN5d
Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples
Novavax Inc. shares climbed 2% on Wednesday and extended gains in after-hours trading, as retail investors maintained a ...